USANA Health Sciences - USNA Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" USNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in USNA, but not buy additional shares or sell existing shares.
View USNA analyst ratings or view top-rated stocks.

3 brokerages have issued twelve-month target prices for USANA Health Sciences' stock. Their USNA share price forecasts range from $53.00 to $122.00. On average, they expect the company's share price to reach $77.33 in the next year. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for USNA or view top-rated stocks among Wall Street analysts.

USANA Health Sciences' stock was trading at $101.20 at the beginning of 2022. Since then, USNA shares have decreased by 43.6% and is now trading at $57.06.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our USNA earnings forecast.

USANA Health Sciences, Inc. (NYSE:USNA) posted its earnings results on Tuesday, July, 26th. The company reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.05 by $0.05. The business had revenue of $264.47 million for the quarter, compared to analyst estimates of $265 million. USANA Health Sciences had a net margin of 8.27% and a trailing twelve-month return on equity of 22.49%. During the same period last year, the business posted $1.87 earnings per share.

USANA Health Sciences declared that its board has approved a stock buyback plan on Tuesday, February 9th 2021, which permits the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 8.2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its stock is undervalued.

USANA Health Sciences issued an update on its second quarter 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share guidance of $1.05-$1.05 for the period, compared to the consensus EPS estimate of $1.26. The company issued revenue guidance of $265.00 million-$265.00 million, compared to the consensus revenue estimate of $272.77 million.

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of USNA stock can currently be purchased for approximately $57.06.

USANA Health Sciences (NYSE:USNA) has a market capitalization of $1.10 billion and generates $1.19 billion in revenue each year. The company earns $116.50 million in net income (profit) each year or $4.54 on an earnings per share basis.

The company employs 1,978 workers across the globe.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The official website for the company is www.usana.com. The company can be reached via phone at (801) 954-7100, via email at investor.relations@usanainc.com, or via fax at 801-954-7300.